Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine

References

1. 1.↵
   2. Bermel RA,
   3. Bakshi R

   . The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 2006;5:158–70 doi:10.1016/S1474-4422(06)70349-0 pmid:16426992

   CrossRefPubMedWeb of Science
2. 2.↵
   2. De Stefano N,
   3. Airas L,
   4. Grigoriadis N, et al

   . Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs 2014;28:147–56 doi:10.1007/s40263-014-0140-z pmid:24446248

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Zivadinov R,
   3. Jakimovski D,
   4. Gandhi S, et al

   . Clinical relevance of brain atrophy assessment in multiple sclerosis: implications for its use in a clinical routine. Expert Rev Neurother 2016;16:777–93 doi:10.1080/14737175.2016.1181543 pmid:27105209

   CrossRefPubMed
4. 4.↵
   2. Uher T,
   3. Blahova-Dusankova J,
   4. Horakova D, et al

   . Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome. J Neurol 2014;261:1735–44 doi:10.1007/s00415-014-7413-9 pmid:24952618

   CrossRefPubMed
5. 5.↵
   2. Sormani MP,
   3. Arnold DL,
   4. De Stefano N

   . Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol 2014;75:43–49 doi:10.1002/ana.24018 pmid:24006277

   CrossRefPubMed
6. 6.↵
   2. Rocca MA,
   3. Battaglini M,
   4. Benedict RH, et al

   . Brain MRI atrophy quantification in MS: from methods to clinical application. Neurology 2017;88:403–13 doi:10.1212/WNL.0000000000003542 pmid:27986875

   Abstract/FREE Full Text
7. 7.↵
   2. Sastre-Garriga J,
   3. Pareto D,
   4. Rovira À

   . Brain atrophy in multiple sclerosis: clinical relevance and technical aspects. Neuroimaging Clin N Am 2017;27:289–300
8. 8.↵
   2. Tsivgoulis G,
   3. Katsanos AH,
   4. Grigoriadis N, et al

   ; HELANI (Hellenic Academy of Neuroimmunology). The effect of disease-modifying therapies on brain atrophy in patients with clinically isolated syndrome: a systematic review and meta-analysis. Ther Adv Neurol Disord 2015;8:193–202 doi:10.1177/1756285615600381 pmid:26557896

   CrossRefPubMed
9. 9.↵
   2. Tsivgoulis G,
   3. Katsanos AH,
   4. Grigoriadis N, et al

   . The effect of disease modifying therapies on brain atrophy in patients with relapsing-remitting multiple sclerosis: a systematic review and meta-analysis. PLoS One 2015;10:e0116511 doi:10.1371/journal.pone.0116511 pmid:25756363

   CrossRefPubMed
10. 10.↵
    2. Zivadinov R,
    3. Dwyer MG,
    4. Bergsland N

    . Brain atrophy measurements should be used to guide therapy monitoring in MS: YES. Mult Scler 2016;22:1522–24 doi:10.1177/1352458516649253 pmid:27335098

    CrossRefPubMed
11. 11.↵
    2. Zivadinov R,
    3. Bergsland N,
    4. Korn JR, et al

    . Feasibility of brain atrophy measurement in clinical routine without prior standardization of the MRI protocol: results from MS-MRIUS, a longitudinal observational, multicenter real-world outcome study in patients with relapsing-remitting MS. AJNR Am J Neuroradiol 2018;39:289–95 doi:10.3174/ajnr.A5442 pmid:29170269

    Abstract/FREE Full Text
12. 12.↵
    2. Gelineau-Morel R,
    3. Tomassini V,
    4. Jenkinson M, et al

    . The effect of hypointense white matter lesions on automated gray matter segmentation in multiple sclerosis. Hum Brain Mapp 2012;33:2802–14 doi:10.1002/hbm.21402 pmid:21976406

    CrossRefPubMed
13. 13.↵
    2. Smith SM,
    3. Zhang Y,
    4. Jenkinson M, et al

    . Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479–89 doi:10.1006/nimg.2002.1040 pmid:12482100

    CrossRefPubMedWeb of Science
14. 14.↵
    2. Dwyer MG,
    3. Silva D,
    4. Bergsland N, et al

    . Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis. Neuroimage Clin 2017;15:769–79 doi:10.1016/j.nicl.2017.06.022 pmid:28706852

    CrossRefPubMed
15. 15.↵
    2. Zivadinov R,
    3. Havrdová E,
    4. Bergsland N, et al

    . Thalamic atrophy is associated with development of clinically definite multiple sclerosis. Radiology 2013;268:831–41 doi:10.1148/radiol.13122424 pmid:23613615

    CrossRefPubMed
16. 16.↵
    2. Dalton CM,
    3. Brex PA,
    4. Jenkins R, et al

    . Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002;73:141–47 doi:10.1136/jnnp.73.2.141 pmid:12122170

    Abstract/FREE Full Text
17. 17.↵
    2. Vollmer T,
    3. Signorovitch J,
    4. Huynh L, et al

    . The natural history of brain volume loss among patients with multiple sclerosis: a systematic literature review and meta-analysis. J Neurol Sci 2015;357:8–18 doi:10.1016/j.jns.2015.07.014 pmid:26238166

    CrossRefPubMed
18. 18.↵
    2. Zivadinov R,
    3. Reder AT,
    4. Filippi M, et al

    . Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 2008;71:136–44 doi:10.1212/01.wnl.0000316810.01120.05 pmid:18606968

    Abstract/FREE Full Text
19. 19.↵
    2. Radue EW,
    3. Sprenger T,
    4. Gaetano L, et al

    . Teriflunomide slows BVL in relapsing MS: a reanalysis of the TEMSO MRI data set using SIENA. Neurol Neuroimmunol Neuroinflamm 2017;4:e390 doi:10.1212/NXI.0000000000000390 pmid:28828394

    CrossRefPubMed
20. 20.↵
    2. Dwyer MG,
    3. Hagemeier J,
    4. Bergsland N, et al

    . Establishing pathological cut-offs for lateral ventricular volume expansion rates. Neuroimage Clin 2018;18:494–501 doi:10.1016/j.nicl.2018.02.009 pmid:29527505

    CrossRefPubMed
21. 21.↵
    2. Weinstock-Guttman B,
    3. Medin J,
    4. Khan N, et al

    . Assessing ‘no evidence of disease activity’ status in patients with relapsing-remitting multiple sclerosis receiving fingolimod in routine clinical practice: a retrospective analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) study. CNS Drugs 2018;32:75–84 doi:10.1007/s40263-017-0482-4 pmid:29270772

    CrossRefPubMed
22. 22.↵
    2. Caramanos Z,
    3. Fonov VS,
    4. Francis SJ, et al

    . Gradient distortions in MRI: characterizing and correcting for their effects on SIENA-generated measures of brain volume change. Neuroimage 2010;49:1601–11 doi:10.1016/j.neuroimage.2009.08.008 pmid:19682586

    CrossRefPubMed
23. 23.↵
    2. Zivadinov R,
    3. Uher T,
    4. Hagemeier J, et al

    . A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients. Mult Scler 2016;22:1709–18 doi:10.1177/1352458516629769 pmid:26883943

    CrossRefPubMed
24. 24.↵
    2. Simon JH,
    3. Jacobs LD,
    4. Campion MK, et al

    . A longitudinal study of brain atrophy in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1999;53:139–48 doi:10.1212/WNL.53.1.139 pmid:10408550

    Abstract/FREE Full Text
25. 25.↵
    2. Brex PA,
    3. Jenkins R,
    4. Fox NC, et al

    . Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology 2000;54:1689–91 doi:10.1212/WNL.54.8.1689 pmid:10762518

    Abstract/FREE Full Text
26. 26.↵
    2. De Stefano N,
    3. Stromillo ML,
    4. Giorgio A, et al

    . Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. J Neurol Neurosurg Psychiatry 2016;87:93–99 doi:10.1136/jnnp-2014-309903 pmid:25904813

    Abstract/FREE Full Text
27. 27.↵
    2. Branger P,
    3. Parienti JJ,
    4. Sormani MP, et al

    . The effect of disease-modifying drugs on brain atrophy in relapsing-remitting multiple sclerosis: a meta-analysis. PLoS One 2016;11:e0149685 doi:10.1371/journal.pone.0149685 pmid:26983008

    CrossRefPubMed
28. 28.↵
    2. De Stefano N,
    3. Giorgio A,
    4. Battaglini M, et al

    . Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 2010;74:1868–76 doi:10.1212/WNL.0b013e3181e24136 pmid:20530323

    Abstract/FREE Full Text
29. 29.↵
    2. Kalkers NF,
    3. Ameziane N,
    4. Bot JC, et al

    . Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. Arch Neurol 2002;59:1572–76 doi:10.1001/archneur.59.10.1572 pmid:12374494

    CrossRefPubMedWeb of Science